Current Report Filing (8-k)
October 28 2020 - 8:59AM
Edgar (US Regulatory)
0001104506
false
0001104506
2020-10-28
2020-10-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 28, 2020
INSMED INCORPORATED
(Exact name of registrant as specified
in its charter)
Virginia
|
|
000-30739
|
|
54-1972729
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
700 US Highway 202/206
|
08807
|
Bridgewater,
New Jersey
|
(Zip Code)
|
(Address of principal executive offices)
|
|
Registrant’s
telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or
former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, par value $0.01 per share
|
|
INSM
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 7.01.
|
Regulation FD Disclosure.
|
On October 28, 2020, Insmed Incorporated
(the “Company”) issued a press release with respect to the announcement summarized in Item 8.01 below. A copy of the
press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information contained herein, including
the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
On October
28, 2020, the Company announced that the European Commission has granted marketing authorization
for ARIKAYCE® Liposomal 590mg Nebuliser Dispersion for the treatment of nontuberculous mycobacterial lung infections caused
by Mycobacterium avium complex in adults with limited treatment options who do not have cystic fibrosis. Consideration should
be given to official guidance on the appropriate use of antibacterial agents.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
INSMED INCORPORATED
|
|
|
|
|
Dated: October 28, 2020
|
By:
|
/s/ Christine Pellizzari
|
|
Name:
|
Christine Pellizzari
|
|
Title:
|
Chief Legal Officer
|
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Insmed (NASDAQ:INSM)
Historical Stock Chart
From Sep 2023 to Sep 2024